{
  "ticker": "PTX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969693",
  "id": "02969693",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250716",
  "time": "0908",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250716/pdf/06lv40qk7dvscg.pdf",
  "summary": "- **First U.S. site initiated** for PTX-100 Phase 2a trial in refractory/relapsed Cutaneous T-Cell Lymphoma (r/r CTCL).  \n- **4 patients already enrolled** across 3 Australian sites.  \n- **Investor briefing scheduled** for 16th July 2025 (2pm AEST).  \n\nNo material financial, capital-raising, or trading-sensitive information identified.",
  "usage": {
    "prompt_tokens": 2696,
    "completion_tokens": 88,
    "total_tokens": 2784,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-15T23:43:39.384347"
}